...
首页> 外文期刊>Intensive Care Medicine >Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome
【24h】

Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome

机译:ICU中需要肾脏替代治疗的患者中的Angiopoietin-2:与急性肾损伤,多器官功能障碍综合征和预后的关系

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose Endothelial activation has emerged as an early event in the pathogenesis of microcirculatory dysfunction, capillary leakage and multi-organ dysfunction syndrome (MODS). Angiopoietin-2 (Ang-2), a circulating antagonistic ligand of the endothelial-specific Tie2 receptor, has been identified as a non-redundant gatekeeper of endothelial activation. On the basis of our previous report demonstrating release of Ang-2 in endotoxemia and sepsis, we aimed to study the utility of Ang-2 to serve as an outcome-specific biomarker in patients requiring renal replacement therapy (RRT) in the intensive care unit (ICU).
机译:目的内皮细胞活化已经成为微循环功能障碍,毛细血管渗漏和多器官功能障碍综合征(MODS)发病机理中的早期事件。血管生成素2(Ang-2),内皮特异性Tie2受体的循环拮抗配体,已被确定为内皮激活的非冗余网守。根据我们先前的报告表明内毒素血症和败血症中Ang-2的释放,我们旨在研究Ang-2在重症监护病房需要肾脏替代疗法(RRT)的患者中作为结局特异性生物标志物的用途(ICU)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号